BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8358723)

  • 1. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
    Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.
    Meyer DL; Law KL; Payne JK; Mikolajczyk SD; Zarrinmayeh H; Jungheim LN; Kling JK; Shepherd TA; Starling JJ
    Bioconjug Chem; 1995; 6(4):440-6. PubMed ID: 7578364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
    Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
    Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
    Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
    Svensson HP; Frank IS; Berry KK; Senter PD
    J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
    Johnson DA; Baker AL; Laguzza BC; Fix DV; Gutowski MC
    Cancer Res; 1990 Mar; 50(6):1790-4. PubMed ID: 2306731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents.
    Meyer DL; Jungheim LN; Mikolajczyk SD; Shepherd TA; Starling JJ; Ahlem CN
    Bioconjug Chem; 1992; 3(1):42-8. PubMed ID: 1616948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
    Apelgren LD; Zimmerman DL; Briggs SL; Bumol TF
    Cancer Res; 1990 Jun; 50(12):3540-4. PubMed ID: 2340502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
    Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
    Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates.
    Carcenac M; Larroque C; Langlois R; van Lier JE; Artus JC; Pèlegrin A
    Photochem Photobiol; 1999 Dec; 70(6):930-6. PubMed ID: 10628305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
    Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
    Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
    Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27.
    Schrappe M; Bumol TF; Apelgren LD; Briggs SL; Koppel GA; Markowitz DD; Mueller BM; Reisfeld RA
    Cancer Res; 1992 Jul; 52(14):3838-44. PubMed ID: 1617657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts].
    Li J; Zhen Y; Yang Z
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Oct; 16(5):328-33. PubMed ID: 7720121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
    Bosslet K; Czech J; Hoffmann D
    Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
    Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon.
    Blumenthal RD; Stein R; Sharkey RM; Goldenberg DM; Ong GL; Klein KM; Mattes MJ
    Cancer Res; 1996 Aug; 56(15):3508-15. PubMed ID: 8758919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.